
MD| IM resident| @accintouch IM program| Aspiring 🫀
Georgia, USA
Joined August 2011
- Tweets14.3K
- Following1.7K
- Followers662
- Likes4.8K
Dolapo retweeted
My sincere thanks to @HFSA and the @JCardFail for the opportunity to lead this work, and to an outstanding writing group of colleagues from across the country for their expertise and dedication. Read the full report: onlinejcf.com/article/S1071-… #HFSTATS #HFSA2026
Replying to @MyJSCAI
Excited to share our study that was recently published in JSCAI, special thanks to @EmiBobManuel2 for the mentorship and special thanks to my awesome co-authors @maxflare @CChinnatambi @wazza_233 @TitaniumMD #cardiology
Dolapo retweeted
A very proud moment: my new proposed definition of MINOCA with the “I” for “injury” and not “infarction”, has been adopted worldwide by the 5th Definition of Myocardial Infarction Guideline by @escardio, @ACCinTouch, @AHAScience @worldheartfed
An important step in making an accurate diagnosis for adequate treatment.
new definition of MINOCA academic.oup.com/eurheartj/a…
Dolapo retweeted
🫀2026 ESC心不全ガイドライン、ついに公表。
2021年版+2023年アップデートから「かなり」変わりました。まず要点だけ👇
✅️HFmrEFが消滅。HFrEF=LVEF <50%、HFpEF=LVEF ≥50%の2分類に
✅️MRAとSGLT2阻害薬がLVEF問わずClass I(HFpEFでは非ステロイド性MRAも可‼️)
✅️GDMTをFMT(基盤治療)とAMT(追加治療)に再定義、デバイス/カテーテル治療はGDIT
✅️肥満合併HFにセマグルチド/チルゼパチド(IIa)が初登場
✅️M-TEERがClass Iに格上げ
✅️心臓リハビリと緩和ケアがClass Iに
✅️ATTR-CMにvutrisiran(silencer)が推奨に追加(Class I A)
詳細はスレッドで🧵
escardio.org/guidelines/clin…
Dolapo retweeted
#SGLT2i 🫱🏾🫲🏽#MRA foundational therapy
as class I recommendation for all patients with HF
irrespective of LVEF
massive workflow implication: implement early after HF syndrome established alongside further LVEF phenotyping!
#ESCGuidelines #ESCCongress
Presented at #ESCCongress:
In patients with atrial fibrillation and intermediate stroke risk, direct oral anticoagulation led to a lower risk of stroke, systemic embolism, major bleeding, or death from cardiovascular causes than no anticoagulation. Full SINGLE-AF trial results: nej.md/4ii61XB
Editorial: Anticoagulation for Atrial Fibrillation with a Single Risk Factor for Stroke nej.md/45FR7D4
@escardio

ALT A graph from the Original Article "Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk." The trial name, SINGLE-AF, is in parentheses after the title. The graph shows the cumulative incidence of primary end-point events (intention-to-treat population). The trial results are being presented at the European Society of Cardiology Congress 2026. The logo of the New England Journal of Medicine is at the bottom.
Dolapo retweeted
🫀Types 1, 2, 3, 4 and 5 myocardial infarction as we knew them are gone.
Perhaps the most important conceptual change presented this morning at #ESCCongress comes from the Fifth Universal Definition of Myocardial Infarction.
The new classification moves away from numbers and toward pathophysiology.
We now have three clinical categories:
Primary MI now includes the complete spectrum of acute primary coronary pathology, not only atherothrombosis.
Plaque rupture or erosion, spontaneous coronary artery dissection, coronary embolism and coronary vasospasm all belong here.
Even restenosis, stent thrombosis or graft failure occurring more than 30 days after a procedure are considered new primary coronary disease rather than late procedural MI.
This fundamentally cleans up one of the problems of the old Type 2 classification.
And Type 2 MI?
The concept becomes secondary myocardial infarction, but importantly with greater diagnostic specificity.
An ICU patient with sepsis, anaemia, hypoxaemia, hypotension, tachyarrhythmia or severe hypertension may have a rise and fall in troponin.
That establishes acute myocardial injury.
It does not automatically establish myocardial infarction.
For secondary MI, the injury must occur in the context of oxygen supply–demand imbalance with evidence supporting myocardial ischaemia, and the new document places much greater emphasis on objective coronary or cardiac imaging when appropriate.
For those of us working with critically ill patients, this distinction matters enormously.
Troponin is a marker of myocardial injury.
Ischaemia makes it myocardial infarction.
The mechanism tells us which infarction we are dealing with.
There are other major changes.
Type 3 MI disappears. Sudden cardiac death suspected to be due to MI should instead be classified as primary, secondary or procedure-related according to the clinical setting or post-mortem findings.
Types 4 and 5 disappear as separate entities. PCI- and surgery-related events are unified under procedure-related MI, applying a common mechanistic framework to cardiac procedures.
And importantly, the old arbitrary troponin thresholds of 5× and 10× the 99th percentile are no longer the basis for defining PCI- and CABG-related MI. The emphasis shifts toward demonstrating a clinically meaningful procedural coronary complication and myocardial consequences.
Another fascinating change:
MINOCA no longer means “myocardial infarction with non-obstructive coronary arteries”..It is now “myocardial injury with non-obstructive coronary arteries.”
A deliberate reminder that MINOCA is a working diagnosis, not an aetiological endpoint.
@European Society of Cardiology
@escardio
#ESCCongress #MyocardialInfarction #Troponin #ACS #CriticalCare #Cardiology @escardio @ACCinTouch @American_Heart @worldheartfed @ehj_ed
@KralerSimon @drmilicaa
Dolapo retweeted
🚨 The 2026 @escardio #HeartFailure Guidelines are here❗️#ESCcongress @secardiologia
1) HFmrEF is gone.
Acute HF is gone.
NT-proBNP cut-offs are now age-adjusted.
Everything that matters 🧵👇
2/ 🔄 NEW DEFINITION — two phenotypes only
❤️🩹 HFrEF → LVEF <50% + symptoms/signs
🫀 HFpEF → LVEF ≥50% + symptoms/signs + objective evidence of structural/functional abnormality
❌ HFmrEF eliminated: same aetiology, same pathophysiology, same treatment response as HFrEF
Dolapo retweeted
NEW: Patient version of 2026 #ESCGuidelines on Cardiac Rehabilitation 👉 ow.ly/iNAI50ZGpKl
This guide applies to adults who are recommended to receive cardiac rehabilitation at a local centre or in their own home as an outpatient.
Please share it with your patients.
#ESCCongress #ESCPatientForum
Dolapo retweeted
NEW 2026 #ESCGuidelines - Fifth Universal Definition of Myocardial Infarction (2026) 👇
ow.ly/yn8J50ZGofb
#ESCCongress
Dolapo retweeted
We are delighted to introduce our amazing #ESCMotions Team at #ESCCongress
👉@rafavidalperez @slumberbell @SMosteoru
@corneliacrm @drmilicaa @Massimi78530343
Follow them to get the good vibes and excitement of #ESCCongress!😄📷
Dolapo retweeted
Tailored Treatment of Myocardial diseases, Endocarditis and Atrial Fibrillation - HOTLINE 1 👇
#ESCCongress
Dolapo retweeted
🚨 Grateful to share that our new paper on DAPT duration after acute coronary syndrome has been published in Cardiovascular Revascularization Medicine!
📈 Across 7 RCTs and 17,515 ACS patients, 3-month DAPT followed by monotherapy performed just as well as 12-month therapy for ischemic protection, while meaningfully reducing bleeding.
✅ Key findings:
MACCE: 5.6% vs 5.7% (RR 0.96; 95% CI 0.79–1.17) — no difference
Clinically relevant bleeding: 3.0% vs 4.9% (RR 0.62; 95% CI 0.50–0.76) — a 38% relative risk reduction, NNT of 52
Net adverse clinical events: 7.9% vs 9.7% (RR 0.81; 95% CI 0.66–1.00)
💡 Trial sequential analysis found:
Conclusive evidence of futility for added ischemic benefit with longer DAPT
Conclusive evidence of benefit for bleeding reduction with abbreviated DAPT
🙏 Grateful to Drs. @IbebuoguMD , @DrDrewKleinPHI , @tristonsmithmd , and Sudhir Mungee for their mentorship and guidance throughout this project, and to my co-authors for their contributions! [@louise_orth ,@sahmIbrah]
Dolapo retweeted
The updated 2026 ACC Expert Consensus Decision Pathway for the Management of #HFpEF reflects a significant evolution in how HFpEF is understood and treated.
Read the full document in #JACC ➡️ bit.ly/3RVs4sl #CardioX
Dolapo retweeted
💬 Editorial: Exercise testing is safe and helps identify physiological limitations in asymptomatic severe #AorticStenosis, supporting more precise risk assessment and intervention planning.
ja.ma/4wkWeEu
Dolapo retweeted
The Lp(a)-lowering drug pipeline is heating up.
💉 Pelacarsen (antisense) — monthly injection, Phase 3, expected FDA approval mid-2027
💉 Olpasiran (siRNA) — quarterly injection, Phase 3, ~2028
💉 Lepodisiran (siRNA) — every 6–12mo injection, Phase 3, ~2029
Dolapo retweeted
🚨❤️ Many US adults are missing their 2026 LDL-C goals!
📊 By risk category (% above goal):
🟡 Low risk — 9.9% (9.7M)
🟠 Borderline/intermediate — 63.6% (32.8M)
🔴 High risk — 82.7% (9.2M)
🟥 Established ASCVD — 79.6% (13.8M)
💊 That's ~65.4M Americans above goal
Dolapo retweeted
The 2026 #Dyslipidemia guideline expands primary prevention #statin eligibility in the US to include more than half of adults aged 30-79 years, including patients with #chronic #kidney #disease and elevated lifetime #ASCVD risk.
ja.ma/3T6RJyE
Dolapo retweeted
The benefits of coffee include lowering the risk of atrial fibrillation, Type 2 diabetes, and lowering blood pressure (J-curve, see summary below)
A summary of the data and statement from @American_Heart ahajournals.org/doi/10.1161/…









































